City Therapeutics Submits Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic Targeting Factor XI for the Treatment of Thromboembolic Diseases City Therapeutics, Inc., a pioneering biopharmaceutical company focused on advancing the field of RNA interference (RNAi)-based medicine, today announced…
Mirum Pharmaceuticals Announces Third Quarter 2025 Results and Highlights Strong Commercial Execution, Pipeline Advancement, and Strategic Positioning for 2026–2027 Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company dedicated to transforming the treatment landscape for rare liver diseases, announced its financial…
Stoke Therapeutics Reports Third Quarter 2025 Results and Highlights Clinical and Corporate Progress Toward Transformational RNA Medicines Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering the use of RNA-based medicines designed to restore healthy protein levels, announced its financial…
enGene Honored by BioSpace as a 2026 Best Place to Work, Underscoring Strong Culture and Mission-Driven Innovation enGene Holdings Inc. (“enGene” or the “Company”) (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, announced that it has been named to the…
QIAGEN to Acquire Parse Biosciences, Expanding Portfolio into Scalable Single-Cell Sequencing and AI-Driven Discovery QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced that it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading U.S.-based innovator in…
Zoetis Appoints Kevin Esch as New R&D President to Succeed Rob Polzer in 2026, Marking a Strategic Leadership Transition in Global Animal Health Innovation Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, announced a major leadership transition in…
Vertex Pharmaceuticals Reports Robust Third Quarter 2025 Results and Refines Full-Year Outlook as Pipeline Momentum Accelerates Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX), a global leader in genetic and transformative medicine, today announced financial results for the third quarter ended September 30,…
Kyowa Kirin International Appoints Julie Dehaene-Puype as President, Ushering in a New Era of Leadership and Growth Kyowa Kirin International (“KKI”), a regional group company of Kyowa Kirin Co., Ltd. (TSE: 4151), a leading Japan-based global specialty pharmaceutical company, has…
Pharmas Hope FDA PreCheck Can Help Avoid Facility-Related Drug Rejections Executives from Eli Lilly, Merck and other companies foresee the FDA’s new onshoring proposal being anything from a bureaucratic waste of time to a transformative program that will eliminate inspection-related…
Study shows Roche Gazyva/Gazyvaro significantly improves outcomes in pediatric and young adult patients with idiopathic nephrotic syndrome. Roche Announces Positive Phase III Results for Gazyva in Idiopathic Nephrotic Syndromeannounced today statistically significant and clinically meaningful results from the phase III…
Gsk Partnership to advance first-in-class siRNA therapy for COPD and other respiratory diseases. GSK plc and Empirico Inc. (Empirico), a clinical-stage biotechnology company with leading capabilities in human genetics-driven target discovery and siRNA medicines, today announced that they have entered…
Health Canada Grants Authorization for LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer’s disease…